Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(02): 40-41
DOI: 10.1055/s-0041-1733166
Letters to Editor

Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients

Julia Dudnik
Department of Oncology, Soroka University, Medical Center Beer Sheva POB 151 84101, Israel 84101
,
Irina Lazarev
Department of Oncology, Soroka University, Medical Center Beer Sheva POB 151 84101, Israel 84101
,
Shmuel Ariad
Department of Oncology, Soroka University, Medical Center Beer Sheva POB 151 84101, Israel 84101
,
Wilmosh Mermershtain
Department of Oncology, Soroka University, Medical Center Beer Sheva POB 151 84101, Israel 84101
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 1997;89:341-43.
  • 2 Mendelsohn, J., Shin, D. M., Donato, N., et al. A Phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). Proc. Am. Soc. Clin. Oncol., 1999;18:1502.
  • 3 Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumour activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 1998;58:2825-31.
  • 4 Slamon, D. J., Leyland-Jones, B., Shak, S., et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., 1998;17: 377.
  • 5 Ciardiello F., Caputo R., Bianco R., et al. Antitumour Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor. Clinical Cancer Research 2000;6(5):2053-63.
  • 6 Fujiwara K., Kiura K, Gemba et al. Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients? Anticancer research 25(1B): 2005;547-49.